Minoxidil için Telogen Effluvium

References

1. [1] Michael M Ong et al.. Am J Clin Dermatol. 2026. Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations. doi:10.1007/s40257-025-00990-4 PubMed
2. [2] Christopher J Thang et al.. J Am Acad Dermatol. 2026. Cardiovascular safety of low-dose oral minoxidil in nonscarring alopecia: A multicenter population-based cohort study using TriNetX. doi:10.1016/j.jaad.2025.08.079 PubMed
3. [3] Caitlin A Kearney et al.. Am J Clin Dermatol. 2026. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. doi:10.1007/s40257-026-01009-2 PubMed
4. [4] Sarah Schaffer et al.. Cureus. 2025. A Scoping Review of Exosome Delivery Applications in Hair Loss. doi:10.7759/cureus.81152 PubMed
5. [5] Luis A Mendoza et al.. Cureus. 2025. Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation. doi:10.7759/cureus.82991 PubMed
6. [6] Xuexue Pan et al.. Aesthetic Plast Surg. 2025. Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation. doi:10.1007/s00266-025-05077-3 PubMed
7. [7] Rui-Xian Guo et al.. Front Pharmacol. 2025. Research progress in the treatment of non-scarring alopecia: mechanism and treatment. doi:10.3389/fphar.2025.1544068 PubMed
8. [8] Yuji Tani et al.. J Dermatol. 2025. Minoxidil Promotes Hair Growth in a Mouse Model of Telogen Effluvium Induced by Lipopolysaccharide. doi:10.1111/1346-8138.70062 PubMed
9. [9] Alondra Saray Polanco-Llanes et al.. Cureus. 2025. Plica Neuropathica (Polonica) Secondary to Diffuse Alopecia: A Case Report and Literature Review. doi:10.7759/cureus.93402 PubMed
10. [10] Adam Leavitt et al.. J Drugs Dermatol. 2025. Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions. doi:10.36849/JDD.8763 PubMed
11. [11] Aliyyat Afolabi et al.. Telemed Rep. 2025. Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study. doi:10.1177/26924366251366793 PubMed
12. [12] Manabu Ohyama et al.. J Dermatol. 2025. Use of 5% Topical Minoxidil Application for Telogen Effluvium: An Open-Label Single-Arm Clinical Trial. doi:10.1111/1346-8138.17844 PubMed
13. [13] Robert J Vanaria et al.. J Cosmet Dermatol. 2025. The Use of Light-Based Therapies in the Treatment of Alopecia. doi:10.1111/jocd.70434 PubMed
14. [14] C D Villarreal-Villarreal et al.. Actas Dermosifiliogr. 2025. Low-Dose Oral Minoxidil as Treatment for COVID-19-Related Telogen Effluvium: Results From a Retrospective Series of 69 Patients. doi:10.1016/j.ad.2025.104569 PubMed
15. [15] Dan Liu et al.. Int J Med Sci. 2024. Status of research on the development and regeneration of hair follicles. doi:10.7150/ijms.88508 PubMed
16. [16] Qin Yang et al.. Regen Biomater. 2024. Dissolvable microneedles loaded ginsenoside Rg3 liposome: a transdermal delivery approach for alopecia treatment. doi:10.1093/rb/rbae086 PubMed
17. [17] Mohammad Amin Jafari et al.. Health Sci Rep. 2024. Efficacy and Safety of Laser Therapy and Phototherapy in Cicatricial and NonCicatricial Alopecia: A Systematic Review Study. doi:10.1002/hsr2.70180 PubMed
18. [18] Shuxuan Li et al.. Int J Pharm. 2024. Panax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation. doi:10.1016/j.ijpharm.2024.124585 PubMed
19. [19] Boutros Soutou et al.. Indian J Dermatol. 2024. Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study. doi:10.4103/ijd.ijd_744_22 PubMed
20. [20] Aarushi K Parikh et al.. Life (Basel). 2024. Advances in Topical Therapies for Clinically Relevant and Prevalent Forms of Alopecia. doi:10.3390/life14121577 PubMed
21. [21] Xuefei Zhang et al.. Int J Nanomedicine. 2024. Resveratrol-Loaded Versatile Nanovesicle for Alopecia Therapy via Comprehensive Strategies. doi:10.2147/IJN.S477820 PubMed
22. [22] Deesha D Desai et al.. Arch Dermatol Res. 2024. Assessing low-dose oral minoxidil efficacy in androgenetic alopecia: a comparative study of AGA and AGA unmasked by telogen effluvium. doi:10.1007/s00403-024-03257-w PubMed
23. [23] Brittany Feaster et al.. Arch Dermatol Res. 2023. Oral minoxidil use in androgenetic alopecia and telogen effluvium. doi:10.1007/s00403-022-02331-5 PubMed
24. [24] S Cedirian et al.. J Cosmet Dermatol. 2023. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic … doi:10.1111/jocd.15873 PubMed
25. [25] Ji Won Lee et al.. J Dermatol. 2023. Hair loss after drug reaction with eosinophilia and systemic symptoms (DRESS): A multicentric retrospective case series. doi:10.1111/1346-8138.16715 PubMed
26. [26] Daranporn Triwongwaranat et al.. Medicine (Baltimore). 2023. Characteristics of hair loss in COVID-19 patients in Thailand. doi:10.1097/MD.0000000000036539 PubMed
27. [27] Michela Starace et al.. Ital J Dermatol Venerol. 2023. Oral supplementation in female telogen effluvium: a clinical and instrumental objective evidence of efficacy and tolerability of new oral cosmetic … doi:10.23736/S2784-8671.22.07416-3 PubMed
28. [28] A K Gupta et al.. J Dermatolog Treat. 2022. Minoxidil: a comprehensive review. doi:10.1080/09546634.2021.1945527 PubMed
29. [29] Belen de Nicolas-Ruanes et al.. J Am Acad Dermatol. 2022. Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. doi:10.1016/j.jaad.2022.04.030 PubMed
30. [30] Manabu Ohyama et al.. J Dermatol. 2022. Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better … doi:10.1111/1346-8138.16475 PubMed
31. [31] Samir Kumar Praharaj et al.. Hum Psychopharmacol. 2022. Valproate-associated hair abnormalities: Pathophysiology and management strategies. doi:10.1002/hup.2814 PubMed
32. [32] Samuel Wei Qiang Ong et al.. Plast Reconstr Surg Glob Open. 2022. COVID-19-induced Scalp Alopecia Treated Effectively with Stem Cell Serum. doi:10.1097/GOX.0000000000004423 PubMed
33. [33] Michael Randolph et al.. J Am Acad Dermatol. 2021. Oral minoxidil treatment for hair loss: A review of efficacy and safety. doi:10.1016/j.jaad.2020.06.1009 PubMed
34. [34] A Villani et al.. J Eur Acad Dermatol Venereol. 2021. Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. doi:10.1111/jdv.17216 PubMed
35. [35] Masoumeh Roohaninasab et al.. Dermatol Ther. 2021. Systematic review of platelet-rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability. doi:10.1111/dth.14768 PubMed
36. [36] Ginny Oong Chien Yin et al.. J Dermatol Sci. 2021. Telogen Effluvium - a review of the science and current obstacles. doi:10.1016/j.jdermsci.2021.01.007 PubMed
37. [37] Peter R Feldman et al.. EClinicalMedicine. 2021. Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial. doi:10.1016/j.eclinm.2021.100978 PubMed
38. [38] Fahham Asghar et al.. Cureus. 2020. Telogen Effluvium: A Review of the Literature. doi:10.7759/cureus.8320 PubMed
39. [39] Ajay N Sharma et al.. Int J Dermatol. 2020. Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. doi:10.1111/ijd.14933 PubMed
40. [40] Jenna R Stoehr et al.. Am J Clin Dermatol. 2019. Off-Label Use of Topical Minoxidil in Alopecia: A Review. doi:10.1007/s40257-018-0409-y PubMed
41. [41] Rodney D Sinclair. Int J Dermatol. 2018. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. doi:10.1111/ijd.13838 PubMed
42. [42] Erkin Pekmezci et al.. Med Arch. 2018. Proprietary Herbal Extract Downregulates the Gene Expression of IL-1α in HaCaT Cells: Possible Implications Against Nonscarring Alopecia. doi:10.5455/medarh.2018.72.136-140 PubMed
43. [43] T Grant Phillips et al.. Am Fam Physician. 2017. Hair Loss: Common Causes and Treatment. PubMed
44. [44] Eshini Perera et al.. F1000Res. 2017. Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. doi:10.12688/f1000research.11775.1 PubMed
45. [45] Michelangelo La Placa et al.. Skin Appendage Disord. 2016. Scalp Psoriasiform Contact Dermatitis with Acute Telogen Effluvium due to Topical Minoxidil Treatment. doi:10.1159/000441622 PubMed
46. [46] Jay C Vary. Med Clin North Am. 2015. Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. doi:10.1016/j.mcna.2015.07.003 PubMed
47. [47] Fernanda Torres et al.. Semin Cutan Med Surg. 2015. Female pattern alopecia and telogen effluvium: figuring out diffuse alopecia. doi:10.12788/j.sder.2015.0142 PubMed
48. [48] Katya L Harfmann et al.. Clin Obstet Gynecol. 2015. Hair loss in women. doi:10.1097/GRF.0000000000000081 PubMed
49. [49] A Rebora. G Ital Dermatol Venereol. 2014. Telogen effluvium revisited. PubMed
50. [50] Nicolas Perez-Mora et al.. Dermatol Ther. 2014. Acute telogen effluvium onset event is associated with the presence of female androgenetic alopecia: potential therapeutic implications. doi:10.1111/dth.12101 PubMed
51. [51] Ingrid Herskovitz et al.. Int J Endocrinol Metab. 2013. Female pattern hair loss. doi:10.5812/ijem.9860 PubMed
52. [52] Archana Singal et al.. Indian J Dermatol Venereol Leprol. 2013. Female pattern hair loss. doi:10.4103/0378-6323.116732 PubMed
53. [53] Shyam Behari Shrivastava. Indian J Dermatol Venereol Leprol. 2009. Diffuse hair loss in an adult female: approach to diagnosis and management. doi:10.4103/0378-6323.45215 PubMed
54. [54] Anne L Mounsey et al.. Am Fam Physician. 2009. Diagnosing and treating hair loss. PubMed
55. [55] Laleh A Bedocs et al.. Curr Opin Pediatr. 2008. Adolescent hair loss. doi:10.1097/MOP.0b013e328305e285 PubMed
56. [56] Bianca Maria Piraccini et al.. Curr Drug Saf. 2006. Drug-induced hair disorders. doi:10.2174/157488606777934477 PubMed
57. [57] V del Marmol et al.. Rev Med Brux. 2004. [Androgenetic alopecia]. PubMed
58. [58] Petra Clara Arck et al.. Exp Dermatol. 2003. Topical minoxidil counteracts stress-induced hair growth inhibition in mice. doi:10.1034/j.1600-0625.2003.00028.x PubMed
59. [59] Antonella Tosti et al.. Arch Dermatol. 2003. Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. doi:10.1001/archderm.139.9.1221 PubMed
60. [60] C Carolyn Thiedke. Am Fam Physician. 2003. Alopecia in women. PubMed
61. [61] Karyn Springer et al.. Am Fam Physician. 2003. Common hair loss disorders. PubMed
62. [62] D H Rushton et al.. Int J Cosmet Sci. 2002. Causes of hair loss and the developments in hair rejuvenation. doi:10.1046/j.0412-5463.2001.00110.x PubMed
63. [63] R M Trüeb. Ther Umsch. 2002. [Diffuse hair loss in women]. doi:10.1024/0040-5930.59.5.217 PubMed
64. [64] M Sommer et al.. Int J Clin Pract. 1999. Therapeutic approaches to the management of common baldness. PubMed
65. [65] S Rand. J Am Acad Dermatol. 1997. Chronic telogen effluvium: potential complication for clinical trials in female androgenetic alopecia? doi:10.1016/s0190-9622(97)70099-9 PubMed
66. [66] A Tosi et al.. Drug Saf. 1994. Drug-induced hair loss and hair growth. Incidence, management and avoidance. doi:10.2165/00002018-199410040-00005 PubMed
67. [67] D H Rushton. Dermatol Clin. 1993. Management of hair loss in women. PubMed
68. [68] A Bardelli et al.. J Am Acad Dermatol. 1989. Telogen effluvium and minoxidil. doi:10.1016/s0190-9622(89)80231-2 PubMed
69. [69] J J Kassimir. J Am Acad Dermatol. 1987. Use of topical minoxidil as a possible adjunct to hair transplant surgery. A pilot study. doi:10.1016/s0190-9622(87)70088-7 PubMed
70. [70] J T Bamford. J Am Acad Dermatol. 1987. A falling out following minoxidil: telogen effluvium. doi:10.1016/s0190-9622(87)80187-1 PubMed